Voyager Technology赢得国际空间站癌症研究实验协议

2026-10-06 21:23

Voyager Technologies (VOYG) announced on Tuesday that it won a contract to manage Symphony Biosciences' cancer research experiment aboard the International Space Station (ISS).
The study will test SymphNode, a device designed to activate T cells to fight cancer, under microgravity conditions.
The company will handle NASA safety reviews, hardware integration, launch preparation, and on-orbit operations.
The deal adds to Voyager’s 1.4K+ missions track record and growing demand for space-based biopharma research.
On the market side, the Voyager stock traded nearly 2% higher at ~$30.71 in the pre-market hours.
Source: Press Release

More on Voyager Technologies, Inc.